LXRX · Lexicon Pharmaceuticals, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Lexicon completed enrollment (significantly over-enrolled) in its Phase 3 SONATA-HCM study of sotagliflozin in HCM, with top-line data expected in Q1 2027, and reiterated 2026 operating expense guidance of $100-$110 million; however, ZYNQUISTA NDA resubmission in type 1 diabetes has shifted to Q4 2026, described as a slight delay from prior timeline.
- + Completed and significantly over-enrolled Phase 3 SONATA-HCM study, with top-line data expected Q1 2027
- + Steno-1 study nearing FDA exposure and DKA thresholds, supporting ZYNQUISTA NDA resubmission in Q4 2026
- + Novo Nordisk progressing LX9851 Phase 1, with potential third $10 million milestone payment later this year
- + Viatris expanding ex-U.S./Europe regulatory approvals and submissions for sotagliflozin in heart failure
- − ZYNQUISTA NDA resubmission shifted to Q4 2026, a slight delay from prior timeline
- − Q2 2026 net loss of $31.8 million vs. net income of $3.3 million in prior year quarter, including $4.3 million loss on early extinguishment of debt
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LXRX
this stock
Lexicon Pharmaceuticals, Inc.
|
$798.70M | +63.0% | +60.2% | — | 6.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LXRX | -9.0% | -14.4% | +6.5% | -16.7% | +63.0% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -8.3% | -14.5% | -5.6% | -16.1% | +51.2% |